ESR1, PIK3CA, and Beyond: Precision Therapy Advances in HR+ Breast Cancer

Hormone receptor-positive (HR+) breast cancer (BC) is the most common subtype of all BC diagnoses, accounting for nearly 70% of all cases. Initial treatment for patients with HR+ BC typically includes CDK4/6 inhibitors, which have led to improved outcomes for patients. However, approximately 50% of patients progress after 18 months of initial treatment. These patients have limited options, underscoring the need for more targeted therapeutic approaches.¹